CMV Infection Treatment Outcomes in Transplant Patients
Part of Genetic & congenital, Hormones & metabolism, Infections clinical trials.
This study tracks how well ganciclovir (an antiviral medicine) works in transplant recipients who develop a resistant CMV infection. Researchers will review medical records to understand treatment success and patient outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You received either an organ transplant (kidney, heart, liver, etc.) or a bone marrow/stem cell transplant
- You developed a CMV infection (a viral complication after transplant) and were treated with ganciclovir or valganciclovir
- Your medical records contain detailed information about your CMV infection, treatment, and blood test results
- Your doctors tracked your health status at 30, 60, or 90 days after your CMV infection was diagnosed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immune cell treatment (CMV-specific cytotoxic T cells) for people with a CMV infection that is not improving despite standard antivirals, or who cannot tolerate them. If eligible, the treatment aims to help the body control the virus after transplant-related immune problems.
This study looks at how to prevent and monitor a virus called CMV after a lung transplant. It is for adults who are not carrying CMV themselves, but who receive lungs from donors who are CMV-positive, and it may help tailor safer follow-up care after transplant.
This trial tests a personalized immune cell treatment (CMV-specific T cells) for people whose CMV (a common herpes virus) persists or comes back after a stem cell transplant. It may help your immune system better control CMV when standard antiviral medicines aren’t fully working or can’t be used.
This study looks at how well a new blood test detects cytomegalovirus (a common virus) in people who have had a stem cell transplant. The test may help doctors catch the virus early and treat it faster.
This study uses a blood test (QuantiFERON-CMV) to help decide whether people with a silent (no symptoms) CMV infection after a solid organ transplant need treatment. If you have a low-to-moderate level of CMV in your blood without fever or organ issues, this trial may help your doctor choose the safest approach.
This trial uses a blood test to measure your immune system's ability to fight CMV, a common virus after transplant. The results will help your doctors decide if you can safely stop taking the antiviral medication letermovir earlier to avoid unnecessary side effects.
Hear when a new Cytomegalovirus Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.